On the public citation graph

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684

0 signed · 110 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/jez.b.21146openalex-snapshot
The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the Mouse ALK RTK
inferredcites →https://doi.org/10.1016/s0002-9440(10)62966-5openalex-snapshot
Biological Role of Anaplastic Lymphoma Kinase in Neuroblastoma
inferredcites →https://doi.org/10.1016/s0002-9440(10)65042-0openalex-snapshot
Expression of the ALK Tyrosine Kinase Gene in Neuroblastoma
inferredcites →https://doi.org/10.1016/s0140-6736(07)60983-0openalex-snapshot
Neuroblastoma
inferredcites →https://doi.org/10.1021/bi8020923openalex-snapshot
ALK Mutants in the Kinase Domain Exhibit Altered Kinase Activity and Differential Sensitivity to Small Molecule ALK Inhibitors
inferredcites →https://doi.org/10.1038/nature07261openalex-snapshot
Identification of ALK as a major familial neuroblastoma predisposition gene
inferredcites →https://doi.org/10.1038/nature07397openalex-snapshot
Activating mutations in ALK provide a therapeutic target in neuroblastoma
inferredcites →https://doi.org/10.1038/nature07398openalex-snapshot
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
inferredcites →https://doi.org/10.1038/nature07399openalex-snapshot
Oncogenic mutations of ALK kinase in neuroblastoma
inferredcites →https://doi.org/10.1038/onc.2010.27openalex-snapshot
Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells
inferredcites →https://doi.org/10.1038/sj.onc.1200849openalex-snapshot
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
inferredcites →https://doi.org/10.1038/sj.onc.1201062openalex-snapshot
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
inferredcites →https://doi.org/10.1038/sj.onc.1205735openalex-snapshot
Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines
inferredcites →https://doi.org/10.1042/bj20081834openalex-snapshot
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours
inferredcites →https://doi.org/10.1042/bj20090387openalex-snapshot
Anaplastic lymphoma kinase: signalling in development and disease
inferredcites →https://doi.org/10.1046/j.1432-1327.2000.01606.xopenalex-snapshot
Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity
inferredcites →https://doi.org/10.1056/nejme1010404openalex-snapshot
Crizotinib — Latest Champion in the Cancer Wars?
inferredcites →https://doi.org/10.1056/nejmoa1006448openalex-snapshot
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1007056openalex-snapshot
Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor
inferredcites →https://doi.org/10.1073/pnas.0609412103openalex-snapshot
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
inferredcites →https://doi.org/10.1074/jbc.m007333200openalex-snapshot
Activation of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Induces Neuronal Differentiation through the Mitogen-activated Protein Kinase Pathway
inferredcites →https://doi.org/10.1074/jbc.m501972200openalex-snapshot
Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin
inferredcites →https://doi.org/10.1074/jbc.m706067200openalex-snapshot
Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase
inferredcites →https://doi.org/10.1093/jnci/djq184openalex-snapshot
ALK, Lung Cancer, and Personalized Therapy: Portent of the Future?
inferredcites →https://doi.org/10.1128/mcb.18.12.6951openalex-snapshot
Nucleophosmin-Anaplastic Lymphoma Kinase of Large-Cell Anaplastic Lymphoma Is a Constitutively Active Tyrosine Kinase That Utilizes Phospholipase C-γ To Mediate Its Mitogenicity
inferredcites →https://doi.org/10.1158/0008-5472.can-06-4443openalex-snapshot
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
inferredcites →https://doi.org/10.1158/0008-5472.can-07-5283openalex-snapshot
Prediction of Cancer Driver Mutations in Protein Kinases
inferredcites →https://doi.org/10.1158/0008-5472.can-10-2366openalex-snapshot
Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-2660openalex-snapshot
Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
inferredcites →https://doi.org/10.1158/1535-7163.mct-07-0365openalex-snapshot
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
inferredcites →https://doi.org/10.1242/jcs.01183openalex-snapshot
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
inferredcites →https://doi.org/10.1593/tlo.11139openalex-snapshot
The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4834038openalex-extracted
Molecular Subtypes of Amino Acid Metabolism-Related Genes Predicting Prognosis, Tumor Microenvironment Composition, and Therapeutic Response in Neuroblastoma
inferred← citeshttps://doi.org/10.1002/1878-0261.12713openalex-snapshot
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer
inferred← citeshttps://doi.org/10.1002/pro.4750openalex-snapshot
Pathogenic mutation hotspots in protein kinase domain structure
inferred← citeshttps://doi.org/10.1007/978-3-031-51292-6_3openalex-snapshot
Genetic Predisposition
inferred← citeshttps://doi.org/10.1007/978-3-319-11888-8_1openalex-snapshot
The ALK Receptor Family
inferred← citeshttps://doi.org/10.1007/s00441-017-2784-8openalex-snapshot
The ALK receptor in sympathetic neuron development and neuroblastoma
inferred← citeshttps://doi.org/10.1007/s00441-018-2820-3openalex-snapshot
Genetic susceptibility to neuroblastoma: current knowledge and future directions
inferred← citeshttps://doi.org/10.1016/b978-0-443-12431-0.00063-2openalex-snapshot
Neuroblastoma
inferred← citeshttps://doi.org/10.1016/b978-1-4557-5414-4.00054-1openalex-snapshot
10.1016/b978-1-4557-5414-4.00054-1
inferred← citeshttps://doi.org/10.1016/j.ajpath.2015.10.016openalex-snapshot
Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma
inferred← citeshttps://doi.org/10.1016/j.ccell.2014.09.019openalex-snapshot
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
inferred← citeshttps://doi.org/10.1016/j.drudis.2017.03.009openalex-snapshot
Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases
inferred← citeshttps://doi.org/10.1016/j.esmoop.2021.100233openalex-snapshot
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature
inferred← citeshttps://doi.org/10.1016/j.gde.2017.03.008openalex-snapshot
Genetic susceptibility to neuroblastoma
inferred← citeshttps://doi.org/10.1016/j.jtho.2018.03.017openalex-snapshot
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation
inferred← citeshttps://doi.org/10.1016/j.molstruc.2014.03.036openalex-snapshot
3D-QSAR and molecular fragment replacement study on diaminopyrimidine and pyrrolotriazine ALK inhibitors
inferred← citeshttps://doi.org/10.1016/j.tips.2016.05.010openalex-snapshot
Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back
inferred← citeshttps://doi.org/10.1017/cbo9781139046947.060openalex-snapshot
Molecular oncology of neuroblastoma
inferred← citeshttps://doi.org/10.1021/acs.jproteome.4c00554openalex-snapshot
Amino Acid Metabolism Subtypes in Neuroblastoma Identifying Distinct Prognosis and Therapeutic Vulnerabilities
inferred← citeshttps://doi.org/10.1038/gim.2017.104openalex-snapshot
A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib
inferred← citeshttps://doi.org/10.1038/nrc3580openalex-snapshot
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
inferred← citeshttps://doi.org/10.1038/nrclinonc.2012.72openalex-snapshot
Targeting ALK in neuroblastoma—preclinical and clinical advancements
inferred← citeshttps://doi.org/10.1038/onc.2012.12openalex-snapshot
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells
inferred← citeshttps://doi.org/10.1038/onc.2015.383openalex-snapshot
PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib
inferred← citeshttps://doi.org/10.1038/s41418-018-0080-0openalex-snapshot
A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment
inferred← citeshttps://doi.org/10.1038/s41598-019-55060-7openalex-snapshot
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
inferred← citeshttps://doi.org/10.1038/s41598-019-57076-5openalex-snapshot
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
inferred← citeshttps://doi.org/10.1038/s41598-020-70890-6openalex-snapshot
Identification of the Wallenda JNKKK as an Alk suppressor reveals increased competitiveness of Alk-expressing cells
inferred← citeshttps://doi.org/10.1038/srep19423openalex-snapshot
Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
inferred← citeshttps://doi.org/10.1055/s-0042-1758542openalex-snapshot
Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance
inferred← citeshttps://doi.org/10.1055/s-0043-1771403openalex-snapshot
Unveiling the Molecular Mechanisms Behind the Devastating Impact of the ALK Protein on Pediatric Cancers: Insights into Deleterious SNPs through In Silico Predictions, Molecular Docking, and Dynamics Studies
inferred← citeshttps://doi.org/10.1074/jbc.m112.391425openalex-snapshot
The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase
inferred← citeshttps://doi.org/10.1080/15384047.2015.1095407openalex-snapshot
Anaplastic lymphoma kinase: Role in cancer and therapy perspective
inferred← citeshttps://doi.org/10.1093/annonc/mdw301openalex-snapshot
The role of the ALK receptor in cancer biology
inferred← citeshttps://doi.org/10.1093/hmg/ddx081openalex-snapshot
PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis
inferred← citeshttps://doi.org/10.1097/ms9.0000000000000222openalex-snapshot
Fruit fly for anticancer drug discovery and repurposing
inferred← citeshttps://doi.org/10.1097/rlu.0000000000001792openalex-snapshot
Variable MIBG Activity in the Same Renal Cyst
inferred← citeshttps://doi.org/10.1101/mcs.a001115openalex-snapshot
ALK: a tyrosine kinase target for cancer therapy
inferred← citeshttps://doi.org/10.1101/mcs.a002550openalex-snapshot
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
inferred← citeshttps://doi.org/10.1101/mcs.a006064openalex-snapshot
Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma
inferred← citeshttps://doi.org/10.1109/jbhi.2021.3100424openalex-snapshot
dbMCS: A Database for Exploring the Mutation Markers of Anti-Cancer Drug Sensitivity
inferred← citeshttps://doi.org/10.1111/apm.12940openalex-snapshot
Targeting anaplastic lymphoma kinase in neuroblastoma
inferred← citeshttps://doi.org/10.1111/febs.12453openalex-snapshot
Phosphoproteomic analysis of anaplastic lymphoma kinase ( ALK ) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells
inferred← citeshttps://doi.org/10.1111/jcmm.17427openalex-snapshot
Penttinen syndrome‐associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling
inferred← citeshttps://doi.org/10.1126/scisignal.aam7550openalex-snapshot
MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)–addicted neuroblastomas
inferred← citeshttps://doi.org/10.1126/scisignal.aar5680openalex-snapshot
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
inferred← citeshttps://doi.org/10.1158/0008-5472.can-14-0241openalex-snapshot
Flotillin-1 Regulates Oncogenic Signaling in Neuroblastoma Cells by Regulating ALK Membrane Association
inferred← citeshttps://doi.org/10.1158/0008-5472.can-14-3817openalex-snapshot
Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-14-1511openalex-snapshot
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-12-0009openalex-snapshot
ALKoma: A Cancer Subtype with a Shared Target
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-15-0235openalex-snapshot
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
inferred← citeshttps://doi.org/10.1186/s12964-025-02150-xopenalex-snapshot
AlkTango reveals a role for Jeb/Alk signaling in the Drosophila heart
inferred← citeshttps://doi.org/10.1186/s13045-016-0254-5openalex-snapshot
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
inferred← citeshttps://doi.org/10.1200/po.21.00271openalex-snapshot
Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
inferred← citeshttps://doi.org/10.1242/dev.094466openalex-snapshot
Jeb/Alk signalling regulates the Lame duck GLI family transcription factor in theDrosophilavisceral mesoderm
inferred← citeshttps://doi.org/10.1242/dmm.010348openalex-snapshot
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
inferred← citeshttps://doi.org/10.1242/dmm.024448openalex-snapshot
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
inferred← citeshttps://doi.org/10.1371/journal.pone.0112250openalex-snapshot
The Drosophila Midkine/Pleiotrophin Homologues Miple1 and Miple2 Affect Adult Lifespan but Are Dispensable for Alk Signaling during Embryonic Gut Formation
inferred← citeshttps://doi.org/10.1371/journal.pone.0121378openalex-snapshot
ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.1517/21678707.2015.1086334openalex-snapshot
Crizotinib: an orphan drug for treating non-small-cell lung cancer
inferred← citeshttps://doi.org/10.17925/ohr.2013.09.2.149openalex-snapshot
The Role of Anaplastic Lymphoma Kinase in Human Cancers
inferred← citeshttps://doi.org/10.18632/oncotarget.14141openalex-snapshot
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent
inferred← citeshttps://doi.org/10.18632/oncotarget.17500openalex-snapshot
ARID1B alterations identify aggressive tumors in neuroblastoma
inferred← citeshttps://doi.org/10.18632/oncotarget.2036openalex-snapshot
Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells
inferred← citeshttps://doi.org/10.18632/oncotarget.8173openalex-snapshot
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
inferred← citeshttps://doi.org/10.18632/oncotarget.8508openalex-snapshot
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells,Drosophilaand mice
inferred← citeshttps://doi.org/10.3389/fonc.2012.00017openalex-snapshot
ALK Inhibitors, a Pharmaceutical Perspective
inferred← citeshttps://doi.org/10.3389/fonc.2019.00579openalex-snapshot
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
inferred← citeshttps://doi.org/10.3389/fonc.2020.00228openalex-snapshot
Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
inferred← citeshttps://doi.org/10.3390/cancers10040113openalex-snapshot
ALK in Neuroblastoma: Biological and Therapeutic Implications
inferred← citeshttps://doi.org/10.3390/cancers15051418openalex-snapshot
Genomics-Driven Precision Medicine in Pediatric Solid Tumors
inferred← citeshttps://doi.org/10.3390/cancers9110149openalex-snapshot
Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation
inferred← citeshttps://doi.org/10.3390/pharmaceutics14091841openalex-snapshot
Kinase Inhibitor Screening Displayed ALK as a Possible Therapeutic Biomarker for Gastric Cancer
inferred← citeshttps://doi.org/10.3410/f.717957514.793461911openalex-snapshot
Faculty Opinions recommendation of The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
inferred← citeshttps://doi.org/10.5772/55300openalex-snapshot
Close Neighbours on Chromosome 2 the ALK and MYCN Genes. Implications for Targeted Therapeutics in Neuroblastoma
inferred← citeshttps://doi.org/10.70675/adcc91cfz8e36z4e52z9782z0ca0390c3a32openalex-snapshot
Role of the mutated ALK oncogene in neuroblastoma oncogenesis and in development
inferred← citeshttps://doi.org/10.70675/df391d10z4dd5z438bzae67zce397bee1d7aopenalex-snapshot
Effets d’inhibiteurs de tyrosine kinase de première et troisième génération associés à l’irradiation dans le cancer du poumon non à petites cellules présentant un réarrangement du gène ALK
inferred← citeshttps://doi.org/10.7554/elife.09811openalex-snapshot
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.